These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 12067953)

  • 1. Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.
    Meinardi MT; Van Der Graaf WT; Gietema JA; Van Den Berg MP; Sleijfer DT; De Vries EG; Haaksma J; Boomsma F; Van Veldhuisen DJ
    Heart; 2002 Jul; 88(1):81-2. PubMed ID: 12067953
    [No Abstract]   [Full Text] [Related]  

  • 2. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
    J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.
    Venturini M; Michelotti A; Del Mastro L; Gallo L; Carnino F; Garrone O; Tibaldi C; Molea N; Bellina RC; Pronzato P; Cyrus P; Vinke J; Testore F; Guelfi M; Lionetto R; Bruzzi P; Conte PF; Rosso R
    J Clin Oncol; 1996 Dec; 14(12):3112-20. PubMed ID: 8955656
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case of epirubicin-induced cardiomyopathy in familial cardiomyopathy.
    Shipman KE; Arnold I
    J Clin Oncol; 2011 Jun; 29(18):e537-8. PubMed ID: 21482996
    [No Abstract]   [Full Text] [Related]  

  • 5. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide.
    Andersen KG; Jensen MB; Kehlet H; Gärtner R; Eckhoff L; Kroman N
    Acta Oncol; 2012 Nov; 51(8):1036-44. PubMed ID: 22676048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
    Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
    J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors.
    Perik PJ; De Vries EG; Boomsma F; van der Graaf WT; Sleijfer DT; van Veldhuisen DJ; Gietema JA
    Anticancer Res; 2005; 25(5):3651-7. PubMed ID: 16101196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
    Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
    J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
    French Adjuvant Study Group
    J Clin Oncol; 2001 Feb; 19(3):602-11. PubMed ID: 11157009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.
    Meinardi MT; van Veldhuisen DJ; Gietema JA; Dolsma WV; Boomsma F; van den Berg MP; Volkers C; Haaksma J; de Vries EG; Sleijfer DT; van der Graaf WT
    J Clin Oncol; 2001 May; 19(10):2746-53. PubMed ID: 11352968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
    Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
    Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy.
    de Azambuja E; Ameye L; Diaz M; Vandenbossche S; Aftimos P; Bejarano Hernández S; Shih-Li C; Delhaye F; Focan C; Cornez N; Vindevoghel A; Beauduin M; Lemort M; Paesmans M; Suter T; Piccart-Gebhart M
    Eur J Cancer; 2015 Nov; 51(17):2517-24. PubMed ID: 26321502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancer.
    Turtle CJ; Keefe DM; Bell D; Wheeler H; Ma DD
    Aust N Z J Med; 1999 Apr; 29(2):275-7. PubMed ID: 10342033
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiotoxicity of epirubicin versus doxorubicin: cost and clinical results.
    Ventura GJ
    J Clin Oncol; 2005 Apr; 23(12):2873; author reply 2873-4. PubMed ID: 15838014
    [No Abstract]   [Full Text] [Related]  

  • 15. Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer.
    Paradiso A; Schittulli F; Cellamare G; Mangia A; Marzullo F; Lorusso V; De Lena M
    J Clin Oncol; 2001 Oct; 19(19):3929-37. PubMed ID: 11579113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term heart function after adjuvant epirubicin chemotherapy for breast cancer.
    Appel JM; Zerahn B; Møller S; Christensen HM; Søgaard P; Ejlertsen B; Fogh-Andersen N; Jensen BV; Nielsen DL
    Acta Oncol; 2012 Nov; 51(8):1054-61. PubMed ID: 22909389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
    Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
    JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recall phenomenon following epirubicin.
    Wilson J; Carder P; Gooi J; Nishikawa H
    Clin Oncol (R Coll Radiol); 1999; 11(6):424-5. PubMed ID: 10663338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of manic episode during treatment with 5-fluorouracil, epirubicin and cyclophosphamide for breast cancer.
    Pacchiarotti I; Mazzarini L; Pellegrini P; Venturelli V; Sani G; Sánchez-Moreno J; Mancinelli I; Tatarelli R; Kotzalidis GD; Girardi P
    Gen Hosp Psychiatry; 2007; 29(5):461-3. PubMed ID: 17888816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Herpes simplex encephalitis as a complication of adjuvant chemotherapy treatment for breast cancer.
    Cathomas R; Pelosi E; Smart J; Murray N; Simmonds P
    Clin Oncol (R Coll Radiol); 2005 Jun; 17(4):292-3. PubMed ID: 15997927
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.